Metabolic Research Peptide
NN9838
CAS: 1415456-99-3
ZP8396
A 37-amino acid long-acting acylated amylin analog that activates amylin and calcitonin receptors to modulate appetite signaling in homeostatic and hedonic brain regions, studied in clinical trials for weight management. Premium Research Peptide.
Third Party Tested by Freedom Diagnostics
Technical specifications
Store frozen or refrigerated
Avoid repeated freeze-thaw
Protect from light
Lyophilized (powder)
Store at -20°C long-term
Reconstituted
2-8°C • use within days
Light protection
Protect from light
Peer-reviewed research
New England Journal of Medicine
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 • DOI: 10.1056/NEJMoa2502081
Garvey WT, Blüher M, Osorto Contrera...
The Lancet
Once-weekly cagrilintide for weight management in people with overweight and obesity: a...
2021 • PMID: 34798060
Lau DCW et al.
The Lancet
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of...
2021 • PMID: 33894838
Enebo LB et al.
Nature Communications
Structural and dynamic features of cagrilintide binding to calcitonin-family receptors
2025
Journal of Medicinal Chemistry
Development of Cagrilintide, a Long-Acting Amylin Analogue
2021
Cardiology in Review
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
2024 • DOI: 10.1097/CRD.0...
PMID: 36883831
D'Ascanio AM, Mullally JA, Frishman...
PMC
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3
2025
PubChem
Cagrilintide — CID 171397054
Novo Nordisk (Press Release)
CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with...
2026
ClinicalTrials.gov
REDEFINE 1 — A Research Study to See How Well CagriSema Works in People Living With Overweight or...
